XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The study is a randomized,multicenter, double-blinded,phase III study. To explore the
affection of vitamin D3 in combination with oxaliplatin plus fluoropyrimidine versus
oxaliplatin plus fluoropyrimidine as first-line chemotherapy in previously untreated advanced
or metastatic colorectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital